Drug intelligence / Profile preview

BSYS-BMSC-exos

Development stage: Preclinical
Modality: Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

BSYS-BMSC-exos is an exosome-based therapeutic agent derived from bone marrow mesenchymal stem cells (BMSCs) that have been modified with the Bu Shen Yi Sui capsule (BSYS). The Bu Shen Yi Sui capsule is a modified traditional Chinese medicine formula. This drug is being investigated for its potential to promote remyelination, particularly in the context of multiple sclerosis (MS). Its mechanism of action involves regulating the miR-15b/Wnt signaling pathway, which in turn mediates the differentiation of oligodendrocytes.

Other names: exosomes of BMSCs modified with Bu Shen Yi Sui capsule

Targets

WNT3A (Wnt family member 3A)

Beyond the preview

Go deeper on BSYS-BMSC-exos.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSYS-BMSC-exos.